nodes	percent_of_prediction	percent_of_DWPC	metapath
Ergotamine—migraine—Prednisone—psoriasis	0.653	1	CpDpCtD
Ergotamine—CYP1A2—Clobetasol propionate—psoriasis	0.05	0.202	CbGbCtD
Ergotamine—CYP1A2—Methoxsalen—psoriasis	0.0263	0.106	CbGbCtD
Ergotamine—CYP3A4—Calcitriol—psoriasis	0.0177	0.0715	CbGbCtD
Ergotamine—CYP3A4—Methoxsalen—psoriasis	0.0138	0.0556	CbGbCtD
Ergotamine—ABCB1—Mycophenolate mofetil—psoriasis	0.0132	0.0533	CbGbCtD
Ergotamine—Localised oedema—Tazarotene—psoriasis	0.0123	0.146	CcSEcCtD
Ergotamine—ABCB1—Betamethasone—psoriasis	0.0113	0.0457	CbGbCtD
Ergotamine—ABCB1—Prednisolone—psoriasis	0.0112	0.0451	CbGbCtD
Ergotamine—ABCB1—Hydrocortisone—psoriasis	0.0106	0.0428	CbGbCtD
Ergotamine—ABCB1—Prednisone—psoriasis	0.0105	0.0426	CbGbCtD
Ergotamine—ABCB1—Cyclosporine—psoriasis	0.01	0.0404	CbGbCtD
Ergotamine—CYP3A4—Cholecalciferol—psoriasis	0.00912	0.0368	CbGbCtD
Ergotamine—CYP3A4—Mycophenolate mofetil—psoriasis	0.00791	0.0319	CbGbCtD
Ergotamine—CYP3A4—Triamcinolone—psoriasis	0.00791	0.0319	CbGbCtD
Ergotamine—CYP3A4—Betamethasone—psoriasis	0.00678	0.0274	CbGbCtD
Ergotamine—CYP3A4—Prednisolone—psoriasis	0.00669	0.027	CbGbCtD
Ergotamine—ABCB1—Dexamethasone—psoriasis	0.00659	0.0266	CbGbCtD
Ergotamine—CYP3A4—Hydrocortisone—psoriasis	0.00634	0.0256	CbGbCtD
Ergotamine—CYP3A4—Prednisone—psoriasis	0.00632	0.0255	CbGbCtD
Ergotamine—CYP3A4—Cyclosporine—psoriasis	0.00599	0.0242	CbGbCtD
Ergotamine—Gangrene—Hydroxyurea—psoriasis	0.00533	0.0633	CcSEcCtD
Ergotamine—ABCB1—Methotrexate—psoriasis	0.00529	0.0214	CbGbCtD
Ergotamine—Distress—Hydroxyurea—psoriasis	0.00419	0.0498	CcSEcCtD
Ergotamine—CYP3A4—Dexamethasone—psoriasis	0.00395	0.0159	CbGbCtD
Ergotamine—Gangrene—Mycophenolate mofetil—psoriasis	0.00353	0.0418	CcSEcCtD
Ergotamine—Emotional distress—Hydroxyurea—psoriasis	0.00274	0.0325	CcSEcCtD
Ergotamine—Paresthesia of limbs—Methotrexate—psoriasis	0.00227	0.027	CcSEcCtD
Ergotamine—Cyanosis—Acitretin—psoriasis	0.0021	0.0249	CcSEcCtD
Ergotamine—Paraesthesia—Calcipotriol—psoriasis	0.00135	0.016	CcSEcCtD
Ergotamine—Hypoaesthesia—Clobetasol propionate—psoriasis	0.00131	0.0156	CcSEcCtD
Ergotamine—Pain—Calcipotriol—psoriasis	0.00128	0.0152	CcSEcCtD
Ergotamine—Cyanosis—Mycophenolate mofetil—psoriasis	0.00109	0.0129	CcSEcCtD
Ergotamine—Pruritus—Calcipotriol—psoriasis	0.00106	0.0126	CcSEcCtD
Ergotamine—Pain—Tazarotene—psoriasis	0.000945	0.0112	CcSEcCtD
Ergotamine—Paraesthesia—Clobetasol propionate—psoriasis	0.000842	0.00999	CcSEcCtD
Ergotamine—Pain—Clobetasol propionate—psoriasis	0.000802	0.00951	CcSEcCtD
Ergotamine—Pruritus—Tazarotene—psoriasis	0.000782	0.00928	CcSEcCtD
Ergotamine—Hypoaesthesia—Acitretin—psoriasis	0.000741	0.00879	CcSEcCtD
Ergotamine—Vertigo—Methoxsalen—psoriasis	0.000735	0.00872	CcSEcCtD
Ergotamine—Pain—Beclomethasone—psoriasis	0.00073	0.00866	CcSEcCtD
Ergotamine—Pain—Fluocinonide—psoriasis	0.000723	0.00858	CcSEcCtD
Ergotamine—Pruritus—Clobetasol propionate—psoriasis	0.000663	0.00787	CcSEcCtD
Ergotamine—Hypertension—Calcitriol—psoriasis	0.000629	0.00747	CcSEcCtD
Ergotamine—Myalgia—Calcitriol—psoriasis	0.00062	0.00736	CcSEcCtD
Ergotamine—Cyanosis—Methotrexate—psoriasis	0.000616	0.00731	CcSEcCtD
Ergotamine—Pruritus—Fluocinonide—psoriasis	0.000598	0.0071	CcSEcCtD
Ergotamine—Vertigo—Fluocinolone Acetonide—psoriasis	0.000581	0.00689	CcSEcCtD
Ergotamine—Myalgia—Acitretin—psoriasis	0.000552	0.00655	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Calcitriol—psoriasis	0.000542	0.00643	CcSEcCtD
Ergotamine—Pain—Calcitriol—psoriasis	0.000509	0.00604	CcSEcCtD
Ergotamine—Nausea—Beclomethasone—psoriasis	0.000507	0.00601	CcSEcCtD
Ergotamine—Bradycardia—Mycophenolic acid—psoriasis	0.000499	0.00592	CcSEcCtD
Ergotamine—Hypoaesthesia—Mycophenolic acid—psoriasis	0.000487	0.00578	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Acitretin—psoriasis	0.000482	0.00572	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Fluocinolone Acetonide—psoriasis	0.000481	0.0057	CcSEcCtD
Ergotamine—Paraesthesia—Acitretin—psoriasis	0.000475	0.00564	CcSEcCtD
Ergotamine—Pruritus—Methoxsalen—psoriasis	0.000472	0.0056	CcSEcCtD
Ergotamine—Pain—Acitretin—psoriasis	0.000452	0.00537	CcSEcCtD
Ergotamine—Pain—Fluocinolone Acetonide—psoriasis	0.000451	0.00535	CcSEcCtD
Ergotamine—Asthenia—Calcitriol—psoriasis	0.000427	0.00506	CcSEcCtD
Ergotamine—Pruritus—Calcitriol—psoriasis	0.000421	0.00499	CcSEcCtD
Ergotamine—Nausea—Methoxsalen—psoriasis	0.000396	0.0047	CcSEcCtD
Ergotamine—Hypoaesthesia—Cyclosporine—psoriasis	0.000394	0.00468	CcSEcCtD
Ergotamine—Bradycardia—Mycophenolate mofetil—psoriasis	0.000393	0.00467	CcSEcCtD
Ergotamine—Hypoaesthesia—Mycophenolate mofetil—psoriasis	0.000385	0.00456	CcSEcCtD
Ergotamine—Vertigo—Mycophenolic acid—psoriasis	0.000383	0.00455	CcSEcCtD
Ergotamine—Asthenia—Acitretin—psoriasis	0.00038	0.0045	CcSEcCtD
Ergotamine—Vomiting—Calcitriol—psoriasis	0.000378	0.00449	CcSEcCtD
Ergotamine—Pruritus—Acitretin—psoriasis	0.000374	0.00444	CcSEcCtD
Ergotamine—Pruritus—Fluocinolone Acetonide—psoriasis	0.000373	0.00443	CcSEcCtD
Ergotamine—Hypertension—Mycophenolic acid—psoriasis	0.000368	0.00437	CcSEcCtD
Ergotamine—Bradycardia—Prednisolone—psoriasis	0.000367	0.00436	CcSEcCtD
Ergotamine—Myalgia—Mycophenolic acid—psoriasis	0.000363	0.00431	CcSEcCtD
Ergotamine—Bradycardia—Hydrocortisone—psoriasis	0.000358	0.00425	CcSEcCtD
Ergotamine—Pain—Hydroxyurea—psoriasis	0.000355	0.00422	CcSEcCtD
Ergotamine—Nausea—Calcitriol—psoriasis	0.000353	0.00419	CcSEcCtD
Ergotamine—Tachycardia—Mycophenolic acid—psoriasis	0.00034	0.00403	CcSEcCtD
Ergotamine—Bradycardia—Triamcinolone—psoriasis	0.000338	0.00401	CcSEcCtD
Ergotamine—Vomiting—Acitretin—psoriasis	0.000336	0.00399	CcSEcCtD
Ergotamine—Vomiting—Fluocinolone Acetonide—psoriasis	0.000335	0.00398	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Mycophenolic acid—psoriasis	0.000317	0.00376	CcSEcCtD
Ergotamine—Nausea—Acitretin—psoriasis	0.000314	0.00373	CcSEcCtD
Ergotamine—Nausea—Fluocinolone Acetonide—psoriasis	0.000313	0.00372	CcSEcCtD
Ergotamine—Paraesthesia—Mycophenolic acid—psoriasis	0.000312	0.00371	CcSEcCtD
Ergotamine—Vertigo—Cyclosporine—psoriasis	0.00031	0.00368	CcSEcCtD
Ergotamine—Bradycardia—Betamethasone—psoriasis	0.000306	0.00363	CcSEcCtD
Ergotamine—Bradycardia—Dexamethasone—psoriasis	0.000306	0.00363	CcSEcCtD
Ergotamine—Vertigo—Mycophenolate mofetil—psoriasis	0.000302	0.00359	CcSEcCtD
Ergotamine—Asthenia—Hydroxyurea—psoriasis	0.000298	0.00354	CcSEcCtD
Ergotamine—Hypertension—Cyclosporine—psoriasis	0.000298	0.00353	CcSEcCtD
Ergotamine—Pain—Mycophenolic acid—psoriasis	0.000298	0.00353	CcSEcCtD
Ergotamine—Myalgia—Cyclosporine—psoriasis	0.000294	0.00348	CcSEcCtD
Ergotamine—Hypertension—Mycophenolate mofetil—psoriasis	0.00029	0.00345	CcSEcCtD
Ergotamine—Myalgia—Mycophenolate mofetil—psoriasis	0.000286	0.0034	CcSEcCtD
Ergotamine—Vertigo—Prednisolone—psoriasis	0.000282	0.00335	CcSEcCtD
Ergotamine—Vertigo—Hydrocortisone—psoriasis	0.000275	0.00327	CcSEcCtD
Ergotamine—Hypertension—Prednisolone—psoriasis	0.000271	0.00322	CcSEcCtD
Ergotamine—Tachycardia—Mycophenolate mofetil—psoriasis	0.000268	0.00318	CcSEcCtD
Ergotamine—Bradycardia—Prednisone—psoriasis	0.000267	0.00316	CcSEcCtD
Ergotamine—Hypertension—Hydrocortisone—psoriasis	0.000265	0.00314	CcSEcCtD
Ergotamine—Vomiting—Hydroxyurea—psoriasis	0.000264	0.00313	CcSEcCtD
Ergotamine—Myalgia—Hydrocortisone—psoriasis	0.000261	0.0031	CcSEcCtD
Ergotamine—Vertigo—Triamcinolone—psoriasis	0.000259	0.00308	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000256	0.00304	CcSEcCtD
Ergotamine—Paraesthesia—Cyclosporine—psoriasis	0.000253	0.003	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.00025	0.00297	CcSEcCtD
Ergotamine—Tachycardia—Prednisolone—psoriasis	0.00025	0.00297	CcSEcCtD
Ergotamine—Asthenia—Mycophenolic acid—psoriasis	0.00025	0.00296	CcSEcCtD
Ergotamine—Hypertension—Triamcinolone—psoriasis	0.000249	0.00296	CcSEcCtD
Ergotamine—Nausea—Hydroxyurea—psoriasis	0.000247	0.00293	CcSEcCtD
Ergotamine—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000247	0.00293	CcSEcCtD
Ergotamine—Pruritus—Mycophenolic acid—psoriasis	0.000246	0.00292	CcSEcCtD
Ergotamine—Myalgia—Triamcinolone—psoriasis	0.000246	0.00292	CcSEcCtD
Ergotamine—Tachycardia—Hydrocortisone—psoriasis	0.000244	0.0029	CcSEcCtD
Ergotamine—Pain—Cyclosporine—psoriasis	0.000241	0.00286	CcSEcCtD
Ergotamine—Vertigo—Betamethasone—psoriasis	0.000235	0.00279	CcSEcCtD
Ergotamine—Vertigo—Dexamethasone—psoriasis	0.000235	0.00279	CcSEcCtD
Ergotamine—Pain—Mycophenolate mofetil—psoriasis	0.000235	0.00279	CcSEcCtD
Ergotamine—Paraesthesia—Prednisolone—psoriasis	0.00023	0.00273	CcSEcCtD
Ergotamine—Tachycardia—Triamcinolone—psoriasis	0.00023	0.00273	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000228	0.0027	CcSEcCtD
Ergotamine—Hypertension—Dexamethasone—psoriasis	0.000226	0.00268	CcSEcCtD
Ergotamine—Hypertension—Betamethasone—psoriasis	0.000226	0.00268	CcSEcCtD
Ergotamine—Paraesthesia—Hydrocortisone—psoriasis	0.000225	0.00267	CcSEcCtD
Ergotamine—Myalgia—Dexamethasone—psoriasis	0.000223	0.00265	CcSEcCtD
Ergotamine—Myalgia—Betamethasone—psoriasis	0.000223	0.00265	CcSEcCtD
Ergotamine—Vomiting—Mycophenolic acid—psoriasis	0.000221	0.00263	CcSEcCtD
Ergotamine—Pain—Prednisolone—psoriasis	0.000219	0.0026	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000215	0.00255	CcSEcCtD
Ergotamine—Pain—Hydrocortisone—psoriasis	0.000214	0.00254	CcSEcCtD
Ergotamine—Paraesthesia—Triamcinolone—psoriasis	0.000212	0.00251	CcSEcCtD
Ergotamine—Tachycardia—Dexamethasone—psoriasis	0.000209	0.00248	CcSEcCtD
Ergotamine—Tachycardia—Betamethasone—psoriasis	0.000209	0.00248	CcSEcCtD
Ergotamine—Nausea—Mycophenolic acid—psoriasis	0.000207	0.00245	CcSEcCtD
Ergotamine—Vertigo—Prednisone—psoriasis	0.000205	0.00243	CcSEcCtD
Ergotamine—Asthenia—Cyclosporine—psoriasis	0.000202	0.0024	CcSEcCtD
Ergotamine—Pain—Triamcinolone—psoriasis	0.000201	0.00239	CcSEcCtD
Ergotamine—Pruritus—Cyclosporine—psoriasis	0.000199	0.00236	CcSEcCtD
Ergotamine—Asthenia—Mycophenolate mofetil—psoriasis	0.000197	0.00234	CcSEcCtD
Ergotamine—Hypertension—Prednisone—psoriasis	0.000197	0.00234	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000195	0.00231	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000195	0.00231	CcSEcCtD
Ergotamine—Pruritus—Mycophenolate mofetil—psoriasis	0.000194	0.00231	CcSEcCtD
Ergotamine—Myalgia—Prednisone—psoriasis	0.000194	0.0023	CcSEcCtD
Ergotamine—Paraesthesia—Betamethasone—psoriasis	0.000192	0.00228	CcSEcCtD
Ergotamine—Paraesthesia—Dexamethasone—psoriasis	0.000192	0.00228	CcSEcCtD
Ergotamine—Pain—Dexamethasone—psoriasis	0.000183	0.00217	CcSEcCtD
Ergotamine—Pain—Betamethasone—psoriasis	0.000183	0.00217	CcSEcCtD
Ergotamine—Tachycardia—Prednisone—psoriasis	0.000182	0.00216	CcSEcCtD
Ergotamine—Asthenia—Hydrocortisone—psoriasis	0.000179	0.00213	CcSEcCtD
Ergotamine—Vomiting—Cyclosporine—psoriasis	0.000179	0.00212	CcSEcCtD
Ergotamine—Pruritus—Hydrocortisone—psoriasis	0.000177	0.0021	CcSEcCtD
Ergotamine—Vomiting—Mycophenolate mofetil—psoriasis	0.000175	0.00207	CcSEcCtD
Ergotamine—Vertigo—Methotrexate—psoriasis	0.000171	0.00203	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Prednisone—psoriasis	0.00017	0.00201	CcSEcCtD
Ergotamine—Asthenia—Triamcinolone—psoriasis	0.000169	0.00201	CcSEcCtD
Ergotamine—Nausea—Cyclosporine—psoriasis	0.000167	0.00198	CcSEcCtD
Ergotamine—Paraesthesia—Prednisone—psoriasis	0.000167	0.00198	CcSEcCtD
Ergotamine—Pruritus—Triamcinolone—psoriasis	0.000167	0.00198	CcSEcCtD
Ergotamine—Nausea—Mycophenolate mofetil—psoriasis	0.000163	0.00194	CcSEcCtD
Ergotamine—Myalgia—Methotrexate—psoriasis	0.000162	0.00193	CcSEcCtD
Ergotamine—Vomiting—Hydrocortisone—psoriasis	0.000159	0.00189	CcSEcCtD
Ergotamine—Asthenia—Dexamethasone—psoriasis	0.000153	0.00182	CcSEcCtD
Ergotamine—Asthenia—Betamethasone—psoriasis	0.000153	0.00182	CcSEcCtD
Ergotamine—Nausea—Prednisolone—psoriasis	0.000152	0.00181	CcSEcCtD
Ergotamine—Pruritus—Dexamethasone—psoriasis	0.000151	0.00179	CcSEcCtD
Ergotamine—Pruritus—Betamethasone—psoriasis	0.000151	0.00179	CcSEcCtD
Ergotamine—Vomiting—Triamcinolone—psoriasis	0.00015	0.00178	CcSEcCtD
Ergotamine—Nausea—Hydrocortisone—psoriasis	0.000149	0.00176	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000142	0.00168	CcSEcCtD
Ergotamine—Nausea—Triamcinolone—psoriasis	0.00014	0.00166	CcSEcCtD
Ergotamine—Paraesthesia—Methotrexate—psoriasis	0.00014	0.00166	CcSEcCtD
Ergotamine—Vomiting—Betamethasone—psoriasis	0.000136	0.00161	CcSEcCtD
Ergotamine—Vomiting—Dexamethasone—psoriasis	0.000136	0.00161	CcSEcCtD
Ergotamine—Asthenia—Prednisone—psoriasis	0.000134	0.00158	CcSEcCtD
Ergotamine—Pain—Methotrexate—psoriasis	0.000133	0.00158	CcSEcCtD
Ergotamine—Pruritus—Prednisone—psoriasis	0.000132	0.00156	CcSEcCtD
Ergotamine—Nausea—Dexamethasone—psoriasis	0.000127	0.00151	CcSEcCtD
Ergotamine—Nausea—Betamethasone—psoriasis	0.000127	0.00151	CcSEcCtD
Ergotamine—Vomiting—Prednisone—psoriasis	0.000118	0.0014	CcSEcCtD
Ergotamine—Asthenia—Methotrexate—psoriasis	0.000112	0.00132	CcSEcCtD
Ergotamine—Nausea—Prednisone—psoriasis	0.000111	0.00131	CcSEcCtD
Ergotamine—Pruritus—Methotrexate—psoriasis	0.00011	0.00131	CcSEcCtD
Ergotamine—Vomiting—Methotrexate—psoriasis	9.89e-05	0.00117	CcSEcCtD
Ergotamine—Nausea—Methotrexate—psoriasis	9.24e-05	0.0011	CcSEcCtD
Ergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	8.54e-06	0.000562	CbGpPWpGaD
Ergotamine—DRD2—Circadian rythm related genes—IL6—psoriasis	8.31e-06	0.000547	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—NDUFA5—psoriasis	8.29e-06	0.000545	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—APOE—psoriasis	8.12e-06	0.000534	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—LEP—psoriasis	8.12e-06	0.000534	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—CARM1—psoriasis	8.08e-06	0.000532	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—NFKBIA—psoriasis	8.02e-06	0.000528	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CCL20—psoriasis	7.94e-06	0.000523	CbGpPWpGaD
Ergotamine—DRD2—GPCR ligand binding—CXCL8—psoriasis	7.9e-06	0.00052	CbGpPWpGaD
Ergotamine—HTR2A—GPCR ligand binding—CXCL8—psoriasis	7.78e-06	0.000512	CbGpPWpGaD
Ergotamine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	7.75e-06	0.00051	CbGpPWpGaD
Ergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	7.75e-06	0.00051	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR ligand binding—CXCL8—psoriasis	7.61e-06	0.000501	CbGpPWpGaD
Ergotamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	7.59e-06	0.000499	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—NFKBIA—psoriasis	7.57e-06	0.000498	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—SOCS1—psoriasis	7.46e-06	0.000491	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—SOCS1—psoriasis	7.3e-06	0.000481	CbGpPWpGaD
Ergotamine—HTR1D—Signaling by GPCR—TYK2—psoriasis	7.11e-06	0.000468	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR ligand binding—CXCL8—psoriasis	7.07e-06	0.000466	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CYP2S1—psoriasis	7.05e-06	0.000464	CbGpPWpGaD
Ergotamine—HTR1B—Signaling by GPCR—TYK2—psoriasis	6.96e-06	0.000458	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—SOCS1—psoriasis	6.86e-06	0.000452	CbGpPWpGaD
Ergotamine—HTR1D—GPCR downstream signaling—CXCL8—psoriasis	6.82e-06	0.000449	CbGpPWpGaD
Ergotamine—ADRA2B—Hemostasis—VEGFA—psoriasis	6.77e-06	0.000446	CbGpPWpGaD
Ergotamine—HTR1B—GPCR downstream signaling—CXCL8—psoriasis	6.68e-06	0.000439	CbGpPWpGaD
Ergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	6.64e-06	0.000437	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—TYK2—psoriasis	6.57e-06	0.000432	CbGpPWpGaD
Ergotamine—HTR2B—Signaling by GPCR—TYK2—psoriasis	6.54e-06	0.000431	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—SOCS1—psoriasis	6.38e-06	0.00042	CbGpPWpGaD
Ergotamine—HTR2B—GPCR downstream signaling—CXCL8—psoriasis	6.27e-06	0.000413	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—TYK2—psoriasis	6.2e-06	0.000408	CbGpPWpGaD
Ergotamine—HTR1D—Signaling by GPCR—CXCL8—psoriasis	6.19e-06	0.000408	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—TYK2—psoriasis	6.09e-06	0.000401	CbGpPWpGaD
Ergotamine—HTR1B—Signaling by GPCR—CXCL8—psoriasis	6.06e-06	0.000399	CbGpPWpGaD
Ergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	5.85e-06	0.000385	CbGpPWpGaD
Ergotamine—ADRA1D—GPCR downstream signaling—CXCL8—psoriasis	5.84e-06	0.000384	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—SOCS1—psoriasis	5.76e-06	0.000379	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—CXCL8—psoriasis	5.72e-06	0.000377	CbGpPWpGaD
Ergotamine—HTR2B—Signaling by GPCR—CXCL8—psoriasis	5.7e-06	0.000375	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—CARM1—psoriasis	5.58e-06	0.000368	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—SOCS1—psoriasis	5.56e-06	0.000366	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—SOCS1—psoriasis	5.54e-06	0.000364	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—APOE—psoriasis	5.51e-06	0.000362	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—LEP—psoriasis	5.51e-06	0.000362	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—TYK2—psoriasis	5.5e-06	0.000362	CbGpPWpGaD
Ergotamine—HTR1F—Signaling by GPCR—IL6—psoriasis	5.44e-06	0.000358	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—CXCL8—psoriasis	5.4e-06	0.000355	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—APOE—psoriasis	5.39e-06	0.000355	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—LEP—psoriasis	5.39e-06	0.000355	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—JUN—psoriasis	5.32e-06	0.00035	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—TYK2—psoriasis	5.31e-06	0.000349	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—CXCL8—psoriasis	5.3e-06	0.000349	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—SOCS1—psoriasis	5.3e-06	0.000349	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—TYK2—psoriasis	5.28e-06	0.000347	CbGpPWpGaD
Ergotamine—ADRA2B—GPCR downstream signaling—CXCL8—psoriasis	5.27e-06	0.000347	CbGpPWpGaD
Ergotamine—ADRA2A—Hemostasis—VEGFA—psoriasis	5.14e-06	0.000338	CbGpPWpGaD
Ergotamine—HTR1E—Signaling by GPCR—IL6—psoriasis	5.13e-06	0.000338	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—NFKBIA—psoriasis	5.13e-06	0.000338	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—NFKB1—psoriasis	5.12e-06	0.000337	CbGpPWpGaD
Ergotamine—ADRA2B—Hemostasis—TP53—psoriasis	5.12e-06	0.000337	CbGpPWpGaD
Ergotamine—HTR1A—GPCR downstream signaling—CXCL8—psoriasis	5.09e-06	0.000335	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—LEP—psoriasis	5.06e-06	0.000333	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—APOE—psoriasis	5.06e-06	0.000333	CbGpPWpGaD
Ergotamine—HTR2C—GPCR downstream signaling—CXCL8—psoriasis	5.06e-06	0.000333	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—TYK2—psoriasis	5.05e-06	0.000333	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—NFKBIA—psoriasis	5.02e-06	0.000331	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—JUN—psoriasis	5.02e-06	0.00033	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—CAT—psoriasis	4.97e-06	0.000327	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—SOCS1—psoriasis	4.89e-06	0.000322	CbGpPWpGaD
Ergotamine—ADRA1B—GPCR downstream signaling—CXCL8—psoriasis	4.84e-06	0.000319	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—NFKB1—psoriasis	4.83e-06	0.000318	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—SOCS1—psoriasis	4.81e-06	0.000316	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—CXCL8—psoriasis	4.79e-06	0.000315	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.78e-06	0.000315	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—NFKBIA—psoriasis	4.72e-06	0.000311	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—LEP—psoriasis	4.71e-06	0.00031	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—APOE—psoriasis	4.71e-06	0.00031	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—SOCS1—psoriasis	4.71e-06	0.00031	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—TYK2—psoriasis	4.66e-06	0.000307	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—VEGFA—psoriasis	4.65e-06	0.000306	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—CXCL8—psoriasis	4.62e-06	0.000304	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—STAT3—psoriasis	4.6e-06	0.000303	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—CXCL8—psoriasis	4.6e-06	0.000302	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—TYK2—psoriasis	4.58e-06	0.000302	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—TYK2—psoriasis	4.49e-06	0.000295	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—CXCL8—psoriasis	4.47e-06	0.000294	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—CARM1—psoriasis	4.46e-06	0.000293	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—CXCL8—psoriasis	4.4e-06	0.00029	CbGpPWpGaD
Ergotamine—HTR2A—GPCR downstream signaling—CXCL8—psoriasis	4.39e-06	0.000289	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—NFKBIA—psoriasis	4.39e-06	0.000289	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—VEGFA—psoriasis	4.38e-06	0.000288	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—SOCS1—psoriasis	4.37e-06	0.000288	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—STAT3—psoriasis	4.34e-06	0.000286	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—CXCL8—psoriasis	4.3e-06	0.000283	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—LEP—psoriasis	4.25e-06	0.00028	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—APOE—psoriasis	4.25e-06	0.00028	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—TYK2—psoriasis	4.2e-06	0.000277	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—TYK2—psoriasis	4.17e-06	0.000274	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.17e-06	0.000274	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—TYK2—psoriasis	4.11e-06	0.000271	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—LEP—psoriasis	4.11e-06	0.00027	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—APOE—psoriasis	4.11e-06	0.00027	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—APOE—psoriasis	4.09e-06	0.000269	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—LEP—psoriasis	4.09e-06	0.000269	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—CXCL8—psoriasis	4.06e-06	0.000267	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—CXCL8—psoriasis	4e-06	0.000263	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—CXCL8—psoriasis	3.99e-06	0.000263	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—NFKBIA—psoriasis	3.96e-06	0.000261	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—LEP—psoriasis	3.91e-06	0.000257	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—APOE—psoriasis	3.91e-06	0.000257	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—CXCL8—psoriasis	3.91e-06	0.000257	CbGpPWpGaD
Ergotamine—ADRA2A—Hemostasis—TP53—psoriasis	3.88e-06	0.000256	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—TYK2—psoriasis	3.86e-06	0.000254	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—APOE—psoriasis	3.86e-06	0.000254	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—NFKBIA—psoriasis	3.83e-06	0.000252	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—NFKBIA—psoriasis	3.81e-06	0.000251	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—CXCL8—psoriasis	3.66e-06	0.000241	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—NFKBIA—psoriasis	3.64e-06	0.00024	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—CXCL8—psoriasis	3.63e-06	0.000239	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—LEP—psoriasis	3.61e-06	0.000237	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—APOE—psoriasis	3.61e-06	0.000237	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—TYK2—psoriasis	3.6e-06	0.000237	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—CXCL8—psoriasis	3.58e-06	0.000236	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—LEP—psoriasis	3.55e-06	0.000233	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—APOE—psoriasis	3.55e-06	0.000233	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—TP53—psoriasis	3.51e-06	0.000231	CbGpPWpGaD
Ergotamine—HTR1D—Signaling by GPCR—IL6—psoriasis	3.48e-06	0.000229	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—APOE—psoriasis	3.47e-06	0.000229	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—LEP—psoriasis	3.47e-06	0.000229	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CARM1—psoriasis	3.44e-06	0.000226	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—CAT—psoriasis	3.44e-06	0.000226	CbGpPWpGaD
Ergotamine—HTR1B—Signaling by GPCR—IL6—psoriasis	3.41e-06	0.000224	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—JUN—psoriasis	3.4e-06	0.000224	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—CXCL8—psoriasis	3.37e-06	0.000221	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—PPARG—psoriasis	3.36e-06	0.000221	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—NFKBIA—psoriasis	3.36e-06	0.000221	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—JUN—psoriasis	3.33e-06	0.000219	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—TP53—psoriasis	3.31e-06	0.000218	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—NFKBIA—psoriasis	3.31e-06	0.000218	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—NFKB1—psoriasis	3.27e-06	0.000215	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—TYK2—psoriasis	3.25e-06	0.000214	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—NFKBIA—psoriasis	3.24e-06	0.000213	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—LEP—psoriasis	3.23e-06	0.000212	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—APOE—psoriasis	3.23e-06	0.000212	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—IL6—psoriasis	3.21e-06	0.000212	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—NFKB1—psoriasis	3.21e-06	0.000211	CbGpPWpGaD
Ergotamine—HTR2B—Signaling by GPCR—IL6—psoriasis	3.2e-06	0.000211	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—TYK2—psoriasis	3.13e-06	0.000206	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—CXCL8—psoriasis	3.13e-06	0.000206	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—JUN—psoriasis	3.13e-06	0.000206	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—TYK2—psoriasis	3.12e-06	0.000205	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—IL6—psoriasis	3.03e-06	0.0002	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—NFKB1—psoriasis	3.01e-06	0.000198	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—NFKBIA—psoriasis	3.01e-06	0.000198	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—TYK2—psoriasis	2.98e-06	0.000196	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—IL6—psoriasis	2.98e-06	0.000196	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—VEGFA—psoriasis	2.97e-06	0.000196	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—STAT3—psoriasis	2.94e-06	0.000194	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—JUN—psoriasis	2.91e-06	0.000192	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—VEGFA—psoriasis	2.91e-06	0.000191	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—STAT3—psoriasis	2.88e-06	0.00019	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—CXCL8—psoriasis	2.83e-06	0.000186	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—NFKB1—psoriasis	2.8e-06	0.000184	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—TYK2—psoriasis	2.75e-06	0.000181	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—CAT—psoriasis	2.74e-06	0.00018	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—VEGFA—psoriasis	2.73e-06	0.00018	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—CXCL8—psoriasis	2.73e-06	0.00018	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—CXCL8—psoriasis	2.71e-06	0.000179	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—TYK2—psoriasis	2.71e-06	0.000178	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—STAT3—psoriasis	2.71e-06	0.000178	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—IL6—psoriasis	2.69e-06	0.000177	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—APOE—psoriasis	2.67e-06	0.000176	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—TYK2—psoriasis	2.65e-06	0.000174	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—JUN—psoriasis	2.63e-06	0.000173	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CXCL8—psoriasis	2.6e-06	0.000171	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—IL6—psoriasis	2.59e-06	0.000171	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—IL6—psoriasis	2.58e-06	0.00017	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—VEGFA—psoriasis	2.54e-06	0.000167	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—JUN—psoriasis	2.54e-06	0.000167	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—NFKB1—psoriasis	2.53e-06	0.000166	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—JUN—psoriasis	2.52e-06	0.000166	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—STAT3—psoriasis	2.52e-06	0.000166	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—IL6—psoriasis	2.47e-06	0.000163	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—TYK2—psoriasis	2.46e-06	0.000162	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—NFKB1—psoriasis	2.44e-06	0.000161	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—NFKB1—psoriasis	2.43e-06	0.00016	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—JUN—psoriasis	2.42e-06	0.000159	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CXCL8—psoriasis	2.4e-06	0.000158	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CXCL8—psoriasis	2.36e-06	0.000155	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—NFKB1—psoriasis	2.33e-06	0.000153	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PPARG—psoriasis	2.32e-06	0.000153	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CXCL8—psoriasis	2.31e-06	0.000152	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—VEGFA—psoriasis	2.3e-06	0.000151	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—IL6—psoriasis	2.28e-06	0.00015	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—STAT3—psoriasis	2.27e-06	0.00015	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—TP53—psoriasis	2.25e-06	0.000148	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—IL6—psoriasis	2.24e-06	0.000148	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—JUN—psoriasis	2.23e-06	0.000147	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—VEGFA—psoriasis	2.22e-06	0.000146	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—VEGFA—psoriasis	2.2e-06	0.000145	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—TP53—psoriasis	2.2e-06	0.000145	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—IL6—psoriasis	2.2e-06	0.000144	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—STAT3—psoriasis	2.19e-06	0.000144	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—JUN—psoriasis	2.19e-06	0.000144	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—STAT3—psoriasis	2.18e-06	0.000144	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—JUN—psoriasis	2.15e-06	0.000141	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CXCL8—psoriasis	2.14e-06	0.000141	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—NFKB1—psoriasis	2.14e-06	0.000141	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—APOE—psoriasis	2.13e-06	0.00014	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CAT—psoriasis	2.12e-06	0.000139	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—VEGFA—psoriasis	2.11e-06	0.000139	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—NFKB1—psoriasis	2.11e-06	0.000139	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—STAT3—psoriasis	2.09e-06	0.000138	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—NFKB1—psoriasis	2.07e-06	0.000136	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—TP53—psoriasis	2.07e-06	0.000136	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—IL6—psoriasis	2.06e-06	0.000135	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—IL6—psoriasis	2.04e-06	0.000134	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—IL6—psoriasis	2.01e-06	0.000132	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—JUN—psoriasis	1.99e-06	0.000131	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—VEGFA—psoriasis	1.95e-06	0.000128	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—STAT3—psoriasis	1.93e-06	0.000127	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—TP53—psoriasis	1.92e-06	0.000126	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—NFKB1—psoriasis	1.92e-06	0.000126	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—VEGFA—psoriasis	1.91e-06	0.000126	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—STAT3—psoriasis	1.9e-06	0.000125	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—IL6—psoriasis	1.89e-06	0.000124	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—VEGFA—psoriasis	1.87e-06	0.000123	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—STAT3—psoriasis	1.86e-06	0.000122	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PPARG—psoriasis	1.86e-06	0.000122	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—IL6—psoriasis	1.76e-06	0.000116	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—VEGFA—psoriasis	1.74e-06	0.000115	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—TP53—psoriasis	1.73e-06	0.000114	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—STAT3—psoriasis	1.72e-06	0.000114	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—TP53—psoriasis	1.67e-06	0.00011	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—TP53—psoriasis	1.67e-06	0.00011	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—APOE—psoriasis	1.64e-06	0.000108	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—TP53—psoriasis	1.59e-06	0.000105	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—IL6—psoriasis	1.59e-06	0.000105	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—IL6—psoriasis	1.53e-06	0.000101	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—IL6—psoriasis	1.52e-06	0.0001	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—TP53—psoriasis	1.47e-06	9.68e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—IL6—psoriasis	1.46e-06	9.61e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—TP53—psoriasis	1.45e-06	9.52e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PPARG—psoriasis	1.43e-06	9.43e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—TP53—psoriasis	1.42e-06	9.32e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—IL6—psoriasis	1.35e-06	8.86e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—IL6—psoriasis	1.32e-06	8.72e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—TP53—psoriasis	1.32e-06	8.66e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—IL6—psoriasis	1.3e-06	8.53e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—IL6—psoriasis	1.2e-06	7.93e-05	CbGpPWpGaD
